论文部分内容阅读
目的 :为观察尿激酶在溶栓治疗急性心肌梗塞中的疗效和不良反应并寻找一种更合适的溶栓方法。方法 :我们对 50例 (AMI)病人进行了第四方案的溶栓治疗 ,所有溶栓病例均符合入选和不入选标准。一旦病例被选择 ,立即给予尿激酶 2 0 0万 u,(10 0万 u静脉推注 ,10 0万 u快速静脉点滴 )。溶栓后观察疗效和副反应。结果 :在已进行的 50例溶栓病例中 ,溶栓疗法的总有效率达 95% ,梗塞血管再通率为 86 % ,不良反应发作率低 ,程度轻。结论 :我们认为第四方案 ,是一种安全、有效的溶栓方法
Objective: To investigate the efficacy and adverse reactions of urokinase in thrombolytic therapy of acute myocardial infarction (AMI) and to find a more suitable thrombolytic method. METHODS: We conducted the thrombolytic therapy of the fourth protocol in 50 patients (AMI) and all thrombolytic cases met the inclusion and non-inclusion criteria. Once the case was selected, urokinase was immediately given 20 million u (10 million u intravenous bolus, 10 million u rapid intravenous drip). Thrombolytic observation of efficacy and side effects. RESULTS: Of the 50 thrombolytic cases that had been performed, the total effective rate of thrombolytic therapy was 95%, the rate of recanalization of the infarct was 86%, and the incidence of adverse reactions was low and to a lesser extent. Conclusion: We think the fourth option is a safe and effective thrombolytic method